Boai NKY Pharmaceuticals Ltd Working Capital to Net Assets Ratio
Boai NKY Pharmaceuticals Ltd working capital to net assets ratio. Boai NKY Pharmaceuticals Ltd (300109) has a Working Capital to Net Assets ratio of 18.8% as of June 2026. Working capital of CN¥624.13 Million (current assets of CN¥1.39 Billion minus current liabilities of CN¥766.85 Million) is measured against net assets of CN¥3.32 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. Check 300109 intangible-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Boai NKY Pharmaceuticals Ltd (2007–2025)
Working capital to net assets ratio of Boai NKY Pharmaceuticals Ltd from 2007 to 2025. This chart shows how Boai NKY Pharmaceuticals Ltd's Working Capital to Net Assets ratio has evolved across 19 annual periods from 2007 to 2025. As of June 2026, the ratio stands at 18.8%, reflecting working capital of CN¥624.13 Million against net assets of CN¥3.32 Billion CNY. See Boai NKY Pharmaceuticals Ltd (300109) liquidity interval to measure how many days the company can operate on defensive assets alone.
Boai NKY Pharmaceuticals Ltd Working Capital to Net Assets Ratio by Year (2007–2025)
Boai NKY Pharmaceuticals Ltd working capital to net assets ratio by year from 2007 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Boai NKY Pharmaceuticals Ltd from 2007 to 2025, covering 19 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Boai NKY Pharmaceuticals Ltd (300109) total assets.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 27.6% | CN¥1.01 Billion | CN¥3.66 Billion | CN¥1.53 Billion | CN¥519.14 Million | ▲ +5.3 pp |
| 2024 | 22.3% | CN¥804.61 Million | CN¥3.61 Billion | CN¥1.51 Billion | CN¥707.14 Million | ▲ +0.7 pp |
| 2023 | 21.6% | CN¥760.05 Million | CN¥3.52 Billion | CN¥1.19 Billion | CN¥426.95 Million | ▼ -8.3 pp |
| 2022 | 29.9% | CN¥931.28 Million | CN¥3.12 Billion | CN¥1.43 Billion | CN¥502.03 Million | ▼ -19.8 pp |
| 2021 | 49.7% | CN¥1.69 Billion | CN¥3.40 Billion | CN¥2.19 Billion | CN¥501.65 Million | ▲ +46.7 pp |
| 2020 | 2.9% | CN¥89.65 Million | CN¥3.08 Billion | CN¥1.09 Billion | CN¥1.00 Billion | ▼ -2.1 pp |
| 2019 | 5.0% | CN¥153.61 Million | CN¥3.05 Billion | CN¥1.13 Billion | CN¥976.69 Million | ▲ +30.8 pp |
| 2018 | -25.8% | CN¥-329.45 Million | CN¥1.28 Billion | CN¥666.34 Million | CN¥995.79 Million | ▼ -26.5 pp |
| 2017 | 0.7% | CN¥9.22 Million | CN¥1.30 Billion | CN¥650.57 Million | CN¥641.36 Million | ▼ -28.1 pp |
| 2016 | 28.8% | CN¥353.13 Million | CN¥1.23 Billion | CN¥410.81 Million | CN¥57.69 Million | ▲ +0.8 pp |
| 2015 | 28.0% | CN¥325.95 Million | CN¥1.16 Billion | CN¥383.75 Million | CN¥57.80 Million | ▲ +7.3 pp |
| 2014 | 20.7% | CN¥82.80 Million | CN¥400.25 Million | CN¥150.24 Million | CN¥67.44 Million | ▼ -1.8 pp |
| 2013 | 22.5% | CN¥84.73 Million | CN¥377.06 Million | CN¥124.91 Million | CN¥40.18 Million | ▼ -6.0 pp |
| 2012 | 28.5% | CN¥103.64 Million | CN¥363.81 Million | CN¥143.55 Million | CN¥39.91 Million | ▼ -21.4 pp |
| 2011 | 49.9% | CN¥174.95 Million | CN¥350.93 Million | CN¥209.63 Million | CN¥34.67 Million | ▼ -29.5 pp |
| 2010 | 79.3% | CN¥264.28 Million | CN¥333.21 Million | CN¥285.91 Million | CN¥21.63 Million | ▲ +61.3 pp |
| 2009 | 18.0% | CN¥11.18 Million | CN¥62.14 Million | CN¥56.81 Million | CN¥45.63 Million | ▼ -10.4 pp |
| 2008 | 28.4% | CN¥12.48 Million | CN¥43.93 Million | CN¥60.00 Million | CN¥47.52 Million | ▲ +68.4 pp |
| 2007 | -40.0% | CN¥-7.12 Million | CN¥17.82 Million | CN¥41.72 Million | CN¥48.84 Million | — |